[Reproductive disorders in the female pig: causes, manifestation, diagnostics and approach in herd health care].

Tierarztl Prax Ausg G Grosstiere Nutztiere

Prof. Dr. Johannes Kauffold, Funktionseinheit Klauentiermedizin, Ambulatorische und Geburtshilfliche Tierklinik, Veterinärmedizinische Fakultät der Universität Leipzig, An den Tierkliniken 29, 04103 Leipzig, E-Mail:

Published: September 2015

Reproductive failure is the most common cause for culling sows from production herds. These failures can affect individual pigs, but can also be a farm problem. Any region of the pig's genital tract can be diseased, with the uterus being the most frequently affected organ. Numerous microorganisms and toxins are known to cause genital pathology in the sow. Although reproduction problems are considered to be multifactorial, recognizing genital pathology is crucial as the first step in the diagnostic workup of reproductive disorders. This contribution briefly reviews the most common genital disorders in the female pig with respect to incidence, pathogenesis and clinical picture. In a second part, the gynaecological examination and the steps in the diagnostic workup are presented.

Download full-text PDF

Source

Publication Analysis

Top Keywords

disorders female
8
female pig
8
genital pathology
8
diagnostic workup
8
[reproductive disorders
4
pig manifestation
4
manifestation diagnostics
4
diagnostics approach
4
approach herd
4
herd health
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Dementia patients often received one clinical diagnosis, yet most of these cases present multiple underlying pathologies. Bringing the transition from clinical-based to biological-based diagnosis holds promise with the diagnostic criteria proposed by the Alzheimer's Association (AA) Revised Criteria for Diagnosis and Staging of Alzheimer's Disease and the Neuronal Synuclein Disease Integrated Staging System (NSD-ISS). This session aims to explore the practical implications of the AA revised criteria for diagnosing and designing clinical trials in Lewy body disease (LBD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!